As a result of this decision, the FDA is no longer enjoined from approving subsequent abbreviated new drug applications. Teva intends to seek a stay of this decision pending further appeals.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index